Free Trial

Atossa Therapeutics (ATOS) Insider Trading & Ownership

Atossa Therapeutics logo
$1.20 -0.08 (-6.25%)
(As of 11/20/2024 ET)

Atossa Therapeutics (NASDAQ:ATOS) Insider Buying and Selling Activity

Current
Insider Ownership
Percentage
7.60%
Number Of
Insiders Buying
(Last 12 Months)
1
Amount Of
Insider Buying
(Last 12 Months)
$44,250.00
Number Of
Insiders Selling
(Last 12 Months)
0
Get ATOS Insider Trade Alerts

Want to know when executives and insiders are buying or selling Atossa Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily.

ATOS Insider Buying and Selling by Quarter

Atossa Therapeutics Insider and Congressional Trades History

Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
4/10/2024Jonathan FinnDirectorBuy25,000$1.77$44,250.00  
(Data available from 1/1/2013 forward)

ATOS Insider Trading Activity - Frequently Asked Questions

The list of insiders at Atossa Therapeutics includes Jonathan Finn. Learn more on insiders at ATOS.

7.60% of Atossa Therapeutics stock is owned by insiders. Learn more on ATOS's insider holdings.

The following insider purchased ATOS shares in the last 24 months: Jonathan Finn ($44,250.00).

Insiders have purchased a total of 25,000 ATOS shares in the last 24 months for a total of $44,250.00 bought.

Atossa Therapeutics Key Executives

  • Dr. Steven C. Quay FCAP (Age 73)
    M.D., Ph.D., Chairman, CEO & President
    Compensation: $1.21M
  • Ms. Heather Rees CPA (Age 51)
    Senior VP of Finance & Principal Accounting Officer
    Compensation: $520.64k
  • Ms. Delly Behen P.H.R.
    Senior Vice President of Administration & HR
  • Mr. Eric Van Zanten
    Vice President of Investor & Public Relations
  • Dr. Richard Graydon M.D.
    Ph.D., Interim Chief Medical Officer


This page (NASDAQ:ATOS) was last updated on 11/21/2024 by MarketBeat.com Staff
From Our Partners